A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Heterozygous Familial Hypercholesterolemia.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Heterozygous Familial Hypercholesterolemia.
The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with heterozygous familial hypercholesterolemia. The primary hypothesis is that enlicitide decanoate is superior to placebo on mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24.
Inclusion Criteria:
Exclusion Criteria:
Indianapolis, Indiana 46237, United States
Troy, Michigan 48098, United States
Lincoln, Nebraska 68506, United States
Winston-Salem, North Carolina 27157, United States
Camperdown, New South Wales 2050, Australia
Clayton, Victoria 3168, Australia
São Paulo, São Paulo 04012-909, Brazil
Santiago, Region M. de Santiago 8330034, Chile
Bogotá, Cundinamarca 110231, Colombia
Brno, Brno-mesto 625 00, Czechia
Szeged, Csongrád megye 6725, Hungary
Debrecen, 4032, Hungary
Amsterdam, North Holland 1105 AZ, Netherlands
Utrecht, 3584 CX, Netherlands
Singapore, Central Singapore 119074, Singapore
Reus, Tarragona 43204, Spain
Taipei City, Taipei 111, Taiwan